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Improvement in analytical performance over successive
generations of assays for cardiac troponin (cTn) has enabled
detection of progressively lower concentrations with accept-
able precision. By expert convention (1), assays designated
as “high-sensitivity” (hs) detect circulating cTn in 50%
of apparently healthy persons, with the diagnostic threshold
for myocardial infarction (MI) set at the 99th percentile in
the population. More sensitive assays have enabled acute
MI to be diagnosed and excluded more rapidly. However,
low-level elevations of hs-Tn (>99th percentile cut-point)
are prevalent in patients with stable structural heart disease,
including stable coronary atherosclerosis, ventricular dys-
function, and ventricular hypertrophy, as well as in acute
cardiopulmonary conditions without coronary thrombosis.
As a result, detection of myocardial injury is increasingly
commonplace in clinical practice (2). This evolving epide-
miology necessitates discrimination of acute myocardial
injury, with ischemia being of principal concern, from
chronic elevation due to other heart disease.
See page 1231
Toward that goal, the Third Universal Deﬁnition of MI
designated the biomarker criteria for acute MI as cTn >99th
percentile cut-point and demonstrating a dynamic (rising
or falling) pattern (2). It is believed that dynamic changes
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Roche Diagnostics.speciﬁed period, will help differentiate between the various
causes of myocardial injury. Improved analytical precision of
cTn assays has made it possible to identify smaller changes
in concentration and supported active investigation of the
diagnostic performance of various delta criteria with gener-
ally encouraging conclusions (3–7). However, an important
“real-world” assessment of the delta by Bjurman et al. (8) in
this issue of the Journal brings several areas of uncertainty
into focus and points to the need for additional research.
It makes inherent sense that acute myocardial injury ought
be associated with changes in cTn concentration early after
the insult (2). Therefore, the ﬁnding of abnormal but stable
concentrations over serial samples should differentiate
chronic elevation in the setting of structural heart disease
from acute injury (2). In contrast, the ﬁnding of a dynamic
pattern should improve the diagnostic speciﬁcity for acute
MI. At least 6 studies (Table 1) have suggested an
improvement in overall diagnostic accuracy by incorporating
a delta criterion at 2 to 6 h; for example, a relative delta
increased positive predictive value for MI from 75.1% to
95.8% (5), and using an absolute change criterion improved
the diagnostic area under the curve from 0.731 to 0.898 (4).
Although criteria of a 20% relative change or an absolute
change in the range of 50% of the 99th percentile (e.g.,
7 to 9 ng/l with hs-TnT) have both performed reasonably
(Table 1), the optimal criteria will vary by individual assay,
time between measurements, and the range of troponin
elevation (e.g., differing with very small vs larger MIs).
These and other uncertainties regarding the delta are re-
ﬂected in present guidelines, which do not recommend
a speciﬁc delta threshold (2).
The study by Bjurman et al. (8) reveals another issue
relevant to clinical adoption. The investigators evaluated the
distribution of delta hs-TnT among 1,178 patients from the
SWEDEHEART (Swedish Web-System for Enhancement
and Development of Evidence-Based Care in Heart Disease
Evaluated According to Recommended Therapies) registry
with a ﬁnal clinical diagnosis of non–ST-segment-elevation
myocardial infarction (NSTEMI). Importantly, the diag-
nostic standard for MI did not include a delta criterion but
rather was based on any hs-TnT >99th percentile in
conjunction with a clinical history and other diagnostic
testing consistent with myocardial ischemia. Incorporating
a 6-h delta as either a 20% change or 9 ng/l, the
investigators found that, despite a local diagnosis of
NSTEMI, 26% of patients did not meet the 20% change
criteria and 12% did not meet the 9 ng/l change criteria. The
lack of change was more common (approximately one-third)
in patients with low hs-TnT (<100 ng/l). The researchers
speculate that the observed lack of change may be due to
later presentations, during a plateau phase. Second, in
a matched group with a diagnosis of noncoronary chest pain,
Bjurman et al. (8) observed a substantially overlapping range
of delta cTn, particularly in patients with peak hs-
TnT <100 ng/l. As a third critical ﬁnding, they found
that hs-TnT >99th percentile, whether accompanied by
Table 1 Studies Suggesting Improvement in Overall Diagnostic Accuracy by Incorporating Delta Criterion at 2 to 6 Hours
Lead Author
Year (Ref. #) Assay Delta Criteria Performance
Proportion (%)
MIs Missed
Using D Criterion* Notes
Apple 2009 (9),
n ¼ 381
cTnI
(VITROS ES,
Ortho-Clinical
Diagnostics)
Baseline and 6 h:
Relative D >30%
Sensitivity 75.0%
Speciﬁcity 90.6%
PPV 55.7%
NPV 95.8%
25% D criterion improved
speciﬁcity from 81%
to 91% with decline
in sensitivity from
94% to 75%.
Keller 2011 (5),
n ¼ 1,818
(1,260 serial)
hsTnI (Abbott
Diagnostics)
Baseline and 3 h:
Relative D 250%,
and relative D 20%,
(Various other relative
D criteria were also
examined)
D Criterion (250%):
Sensitivity 32.6%
Speciﬁcity 99.6%
PPV 95.8%
NPV 83.7%
D Criterion (20%):
Sensitivity 60.3%
Speciﬁcity 96.8%
PPV 84.6%
NPV 89.4%
D Criterion (250%): 67%
D Criterion (20%): 40%
A high relative D criterion
improved PPV from
75.1% to 95.8% at
expense of sensitivity.
Reichlin 2011 (3),
n ¼ 836
(590 serial)
hsTnT (Roche)
and cTnI
(TnI-Iltra,
Siemens)
Baseline and 2 h:
Absolute D
hs-cTnT: 7 ng/l
cTnI: 20 ng/l
hs-cTnT
Sensitivity 89%
Speciﬁcity 93%
PPV 64%
NPV 98%
TnI-Ultra
Sensitivity 93%
Speciﬁcity 91%
PPV 58%
NPV 99%
hs-cTnT: 10%
TnI-Ultra: 7%
Absolute D had higher
diagnostic accuracy
compared to relative D.
Eggers 2011 (7),
n ¼ 454
cTnI (Stratus CS,
Siemens)
Baseline with 24 h:
Relative D 20%
Sensitivity 95%
Speciﬁcity 92%
PPV 85%
NPV 98%
5%
Mueller 2012 (4),
n ¼ 784
hsTnT (Roche) Baseline and 6 h:
Absolute D 9.2 ng/l
Relative D 20%
Absolute D
Sensitivity 89.7%
Speciﬁcity 74.8%
PPV 48.7%
NPV 96.5%
Relative D (20%)
Sensitivity 75.2%
Speciﬁcity 58.1%
PPV 32.4%
NPV 89.8%
Absolute D: 10%
Relative D: 25%
Optimized absolute D
appeared superior to
optimized relative D.
Optimized relative
criterion was 40% D.
Cullen 2013 (6),
n ¼ 874
cTnI (AccuTnI,
Beckman)
Baseline and 2 h:
Absolute D 30 ng/l
Sensitivity 77.1%
Speciﬁcity 95.8%
PPV 61.4%
NPV 98.0%
23% Absolute D had higher
diagnostic accuracy
compared to relative D.
Bjurman 2013 (8),
n ¼ 1,178
hsTnT (Roche) Baseline and 6 h:
Relative D 20%
Absolute D 9 ng/l
NA Relative D: 26%
Absolute D: 12%
*Derived from data reported in Bjurman et al. (8).
cTn ¼ cardiac troponin; hs-TnT ¼ high-sensitivity troponin T; NPV ¼ negative predicted value; PPV ¼ positive predicted value.
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1240a delta or not, was associated with higher long-term
mortality.
So how do we integrate these ﬁndings into the cumulative
evidence examining delta cTn? The data from Bjurman et al.
(8) indicate that between 10% and 25% of patients with MI
could be missed if meeting a delta cTn criterion were
required, and they raise caution against strict use of the delta
to exclude MI in patients with an otherwise high clinical
probability. However, limitations of the study should be
recognized. In this retrospective study, diagnosis was based
on clinical routine and not formally adjudicated. Also,
sampling windows were at the clinician’s discretion. Becausea rising or falling pattern was not required for diagnosis
of MI, it is possible that patients with chronic stable
elevations of cTn were misclassiﬁed as MI. Nevertheless, as
a counterpoint, studies of delta criteria referenced against
deﬁnitions that incorporate a changing pattern may analo-
gously be critiqued for potentially overstating the diagnostic
performance of the delta. This lack of a biomarker-
independent “gold standard” is challenging in all diag-
nostic studies evaluating biomarker strategies. Moreover, the
proportion of MIs undetected by the delta in the Bjurman
et al. (8) study is similar to data extracted from prior, more
positively framed results (Table 1). In addition, even if one
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1241were to assume diagnostic misclassiﬁcation in the Bjurman
et al. (8) study, it is noteworthy that the mortality rate was
highest among patients with low hs-TnT values that were
stable (<20% delta). Although serial changes may assist
clinicians in differentiating between etiologies of injury, the
lack of change should not be interpreted as indicative of low
risk.
The study by Bjurman et al. (8) also reveals striking
overlap between the distribution of delta cTn in coronary
and noncoronary cases of myocardial injury and speaks
to challenges in using a dynamic biomarker pattern to
discriminate MI from other causes of acute myocardial injury
such as pulmonary embolism or myocarditis. These other
causes may be under-recognized in diagnostic studies that
equate an elevated cTn and dynamic changes to a diagnosis
of MI, thus overstating clinical speciﬁcity of the criteria.
Use of a cTn delta criterion to aid in the diagnosis of MI
has a compelling rationale and has improved overall diag-
nostic accuracy in several studies. However, as reinforced by
the provocative data from the Bjurman et al. study (8),
further investigation and reﬁnement are necessary before
deﬁnitive criteria can be reliably recommended. Neverthe-
less, assessment of serial changes is often valuable when
using cTn diagnostically. A signiﬁcant delta over 2 to 6 h is
diagnostic of acute myocardial injury, whatever the cause,
and supports the diagnosis of MI in the setting of a clinical
story indicative of ischemia. As a rule of thumb, a minimum
of a 20% change is a reasonable delta criterion, although
larger changes deliver higher positive predictive value and
absolute change criteria may perform better at extreme (low
or high) concentrations. Deﬁning optimal cut-points
requires additional study for each assay. Completed studies
reveal an inherent tradeoff favoring greater speciﬁcity at the
expense of sensitivity with higher delta criteria. When serial
cTn values are ﬂat, chronic elevation due to structural heart
disease should be considered. However, elevation of cTn with
a presentation that is concerning for an acute cardiopulmo-
nary cause appears to be associated with adverse short-term
prognosis, whether the cTn is stable or dynamic. Therefore,strategies that include early discharge for patients with
abnormal but stable values of cTn require a thorough inves-
tigation before considered for routine practice. Ultimately,
interpretation of both the magnitude and the pattern of
cTn elevation in the overall clinical context is the mainstay of
diagnosis.
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